{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0|[[File:Bethbuchbinder.jpg|frameless|upright=0.3|center]]
|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn]
|-
|}
''Are you looking for a regimen, but can't find it here? It is possible that we've moved it to the [[Melanoma_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''
<big>'''Note: some melanoma regimens can be found on dedicated pages:
*'''[[Melanoma,_BRAF-mutated|BRAF-mutated melanoma]]
*'''[[Melanoma,_NRAS-mutated|NRAS-mutated melanoma]]
*'''[[CNS melanoma]]
</big>

{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==EDF/EADO/EORTC==
*'''2016:''' [https://www.ejcancer.com/article/S0959-8049(16)32136-0/fulltext Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016] [https://www.ncbi.nlm.nih.gov/pubmed/27367293 PubMed]
==[http://www.esmo.org/ ESMO]==
*'''2015:''' [http://annonc.oxfordjournals.org/content/26/suppl_5/v126.full.pdf+html Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/26314774 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf NCCN Guidelines - Cutaneous Melanoma]

=Adjuvant therapy=

==Interferon alfa-2a monotherapy {{#subobject:67406e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 12 months {{#subobject:ae58d1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/16/4/1425.long Pehamberger et al. 1998]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior DFS
|-
|}
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Interferon alfa-2a (Roferon-A)]] as follows:
**Weeks 1 to 3: 3,000,000 international units SC once per day (21 doses total)
**Weeks 4 to 52: 3,000,000 international units SC three times per week

'''12-month course'''

===Variant #2, 18 months {{#subobject:65fe20|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)12445-X/fulltext Grob et al. 1998]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#d9ef8b"|Might have superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.23.1704 Hauschild et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|IFN alfa-2a x 5 y
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Interferon alfa-2a (Roferon-A)]] 3,000,000 international units SC three times per week

'''18-month course'''

===Variant #3, 24 months {{#subobject:459627|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|rowspan=2|[https://academic.oup.com/annonc/article/19/6/1195/158024 Garbe et al. 2008]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Dacarbazine & IFN alfa-2a
| style="background-color:#d3d3d3" |Not reported
|
|-
|2. [[#Observation|Observation]]
| style="background-color:#1a9850" |Superior OS
|
|-
|[https://academic.oup.com/annonc/article/27/8/1625/2237740 Eigentler et al. 2016 (ML17840)]
|style="background-color:#1a9851"|Phase III (C)
|Peginterferon alfa-2a
|style="background-color:#ffffbf"|Seems not superior
|style="background-color:#1a9850"|Superior toxicity
|-
|}
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]], within 3 months
====Immunotherapy====
*[[Interferon alfa-2a (Roferon-A)]] 3,000,000 international units SC three times per week

'''24-month course'''

===References===
# Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Auböck J, Fritsch P, Kerl H, Wolff K; Austrian Malignant Melanoma Cooperative Group. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol. 1998 Apr;16(4):1425-9. [http://jco.ascopubs.org/content/16/4/1425.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9552047 PubMed]
# Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ; French Cooperative Group on Melanoma. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet. 1998 Jun 27;351(9120):1905-10. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)12445-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9654256 PubMed]
# Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler T, Ellwanger U, Hauschild A. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008 Jun;19(6):1195-201. Epub 2008 Feb 14. [https://academic.oup.com/annonc/article/19/6/1195/158024 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18281266 PubMed]
# Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol. 2010 Feb 10;28(5):841-6. Epub 2010 Jan 4. [http://ascopubs.org/doi/full/10.1200/JCO.2009.23.1704 link to original article] '''contains protocol'''  [https://www.ncbi.nlm.nih.gov/pubmed/20048184 PubMed]
# '''ML17840:''' Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hölzle E, Kiecker F, Becker J, Sunderkötter C, Moll I, Richtig E, Pönitzsch I, Pehamberger H, Kaufmann R, Pföhler C, Vogt T, Berking C, Praxmarer M, Garbe C; Dermatologic Cooperative Oncology Group (DeCOG). Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol. 2016 Aug;27(8):1625-32. Epub 2016 Jun 10. [https://academic.oup.com/annonc/article/27/8/1625/2237740 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27287206 PubMed]

==Interferon alfa-2b monotherapy {{#subobject:86bbbb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
HDI: '''<u>H</u>'''igh-'''<u>D</u>'''ose '''<u>I</u>'''nterferon
===Example orders===
*[[Example orders for adjuvant Interferon alfa-2b (Intron-A) in melanoma]]

===Variant #1, 3M, 6-month course {{#subobject:1eabea|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363881/ Cameron et al. 2001 (The Scottish study)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: The PubMed version of Cameron et al. 2001's abstract says that interferon alfa-2b is given "twice weekly," in contrast to what the actual paper says, "thrice weekly." This is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority.''
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Interferon alfa-2b (Intron-A)]] 3,000,000 units SC three times per week

'''6-month course'''

===Variant #2, 3M, 18-month course {{#subobject:ba9a40|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(12)00601-6/fulltext Grob et al. 2012 (EADO 2001/CMII)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Peginterferon_alfa-2b_monotherapy|Peginterferon x 36 mo]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Interferon alfa-2b (Intron-A)]] 3,000,000 units SC three times per week

'''18-month course'''

===Variant #3, 10M/5M, 24-month course {{#subobject:5f0b6e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67482-X/fulltext Eggermont et al. 2005 (EORTC 18952)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#d9ef8b" |Might have superior OS (*)
|-
|}
''Note: efficacy is based on the 2016 update.''
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Interferon alfa-2b (Intron-A)]] as follows:
**Weeks 1 to 4: 10,000,000 units/m<sup>2</sup> (route not specified) five times per week
**Weeks 5 to 104: 5,000,000 units/m<sup>2</sup> (route not specified) three times per week

'''24-month course'''

===Variant #4, 10M/10M, 12-month course {{#subobject:9dcc46|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67482-X/fulltext Eggermont et al. 2005 (EORTC 18952)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#d9ef8b" |Might have superior OS (*)
|-
|}
''Note: efficacy is based on the 2016 update.''
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Interferon alfa-2b (Intron-A)]] as follows:
**Weeks 1 to 4: 10,000,000 units/m<sup>2</sup> (route not specified) five times per week
**Weeks 5 to 52: 10,000,000 units/m<sup>2</sup> (route not specified) three times per week

'''12-month course'''

===Variant #5, 15M, 4-week course {{#subobject:221b09|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.16.3121 Pectasides et al. 2009]
|style="background-color:#1a9851"|Phase III (E)
|Interferon alfa-2b 15M/10M x 12 mo
|style="background-color:#eeee01"|Non-inferior RFS
|-
|}
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Interferon alfa-2b (Intron-A)]] 15,000,000 units/m<sup>2</sup> IV five times per week

'''4-week course'''

===Variant #6, 20M, 4-week course {{#subobject:7bef92|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684/ Agarwala et al. 2017 (ECOG-ACRIN E1697)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority.''
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Interferon alfa-2b (Intron-A)]] 20,000,000 units/m<sup>2</sup> IV five times per week

'''4-week course'''

===Variant #7, 20M/10M, 12-month course {{#subobject:d28e4a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/14/1/7.long Kirkwood et al. 1996 (ECOG E1684)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[http://ascopubs.org/doi/10.1200/JCO.2001.19.9.2370 Kirkwood et al. 2001 (ECOG E1694)]
|style="background-color:#1a9851"|Phase III (C)
|GM2-KLH/QS-21 vaccine
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226807/ Flaherty et al. 2014 (SWOG S0008)]
|style="background-color:#1a9851"|Phase III (C)
|Biochemotherapy
| style="background-color:#fc8d59" |Seems to have inferior RFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.59.6932 Mohr et al. 2015 (DeCOG MM-ADJ-5)]
|style="background-color:#1a9851"|Phase III (C)
|Intermittent HDI
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321066/ McMasters et al. 2016 (Sunbelt)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Interferon alfa-2b (Intron-A)]] as follows:
**Weeks 1 to 4: 20,000,000 units/m<sup>2</sup> IV five times per week
**Weeks 5 to 52: 10,000,000 units/m<sup>2</sup> SC three times per week

'''12-month course'''

===References===
# '''ECOG E1684:''' Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7-17. [http://jco.ascopubs.org/content/14/1/7.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8558223 PubMed]
# '''ECOG E1690:''' Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun;18(12):2444-58. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2444 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10856105 PubMed]
# '''ECOG E1694:''' Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 1;19(9):2370-80. [http://ascopubs.org/doi/10.1200/JCO.2001.19.9.2370 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11331315 PubMed]
# '''The Scottish Study:''' Cameron DA, Cornbleet MC, Mackie RM, Hunter JA, Gore M, Hancock B, Smyth JF; Scottish Melanoma Group. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer. 2001 May 4;84(9):1146-9. [https://www.nature.com/bjc/journal/v84/n9/full/6691623a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363881/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/11379605 PubMed]
# '''EORTC 18952:''' Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005 Oct 1;366(9492):1189-96. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67482-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16198768 PubMed]
## '''Update:''' Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer. 2016 Mar;55:111-21. [https://www.ejcancer.com/article/S0959-8049(15)01044-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26790144 PubMed]
# Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, Kalofonos H, Fountzilas G, Panagiotou P, Kokkalis G, Papadopoulos O, Castana O, Papadopoulos S, Stavrinidis E, Vourli G, Ioannovich J, Gogas H. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009 Feb 20;27(6):939-44. Epub 2009 Jan 12. [http://ascopubs.org/doi/full/10.1200/JCO.2008.16.3121 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19139440 PubMed]
# '''EADO 2001/CMII:''' Grob JJ, Jouary T, Dréno B, Asselineau J, Gutzmer R, Hauschild A, Leccia MT, Landthaler M, Garbe C, Sassolas B, Herbst RA, Guillot B, Chene G, Pehamberger H. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer. 2013 Jan;49(1):166-74. Epub 2012 Sep 10. [https://www.ejcancer.com/article/S0959-8049(12)00601-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22975216 PubMed]
# '''SWOG S0008:''' Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014 Nov 20;32(33):3771-8. Epub 2014 Oct 20. [http://ascopubs.org/doi/full/10.1200/JCO.2013.53.1590 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226807/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25332243 PubMed]
# '''DeCOG MM-ADJ-5:''' Mohr P, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, Gutzmer R, Brockmeyer N, Hölzle E, Sunderkötter C, Mauch C, Stein A, Schneider LA, Podda M, Göppner D, Schadendorf D, Weichenthal M. Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III melanoma: final analysis of a randomized phase III Dermatologic Cooperative Oncology Group trial. J Clin Oncol. 2015 Dec 1;33(34):4077-84. Epub 2015 Oct 26. [http://ascopubs.org/doi/full/10.1200/JCO.2014.59.6932 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26503196 PubMed]
# '''Sunbelt:''' McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RC 2nd, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Davidson BS, Gershenwald JE, Hagendoorn LJ, Stromberg AJ, Scoggins CR. Final results of the Sunbelt melanoma trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol. 2016 Apr 1;34(10):1079-86. Epub 2016 Feb 8. [http://ascopubs.org/doi/full/10.1200/JCO.2015.63.3776 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321066/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26858331 PubMed]
# '''ECOG-ACRIN E1697:''' Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM. Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10;35(8):885-892. Epub 2017 Jan 30. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.2951 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28135150 PubMed]

==Ipilimumab monotherapy {{#subobject:89bbc6|Regimen=1}}==
{{#subobject:f92245|Variant=1}}
{{#subobject:a17a88|Variant=1}}
{{:Ipilimumab (Yervoy) for melanoma, adjuvant}}

==Nivolumab monotherapy {{#subobject:2b3899|Regimen=1}}==
{{#subobject:a228d5|Variant=1}}
{{:Nivolumab (Opdivo) for melanoma, adjuvant}}

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM197601292940501 Eilber et al. 1976]
|style="background-color:#1a9851"|Randomized (C)
|BCG
| style="background-color:#fc8d59" |Seems to have inferior MFS
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJM198210073071503 Veronesi et al. 1982]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. BCG
|style="background-color:#ffffbf"|Seems not superior
|-
|2. BCG & Dacarbazine
|style="background-color:#ffffbf"|Seems not superior
|-
|3. Dacarbazine
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.5.729 Quirt et al. 1991]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. BCG<br> 2. BCG/Levamisole<br> 
|style="background-color:#ffffbf"|Seems not superior
|-
|3. Levamisole
|style="background-color:#fee08b"|Might have inferior OS
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.10.2060 Meyskens et al. 1994 (SWOG S8049)]
|style="background-color:#1a9851"|Phase III (C)
|Vitamin A
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/10.1200/JCO.1995.13.11.2776 Creagan et al. 1995]
|style="background-color:#1a9851"|Phase III (C)
|[[#Interferon_alfa-2a_monotherapy|Interferon alfa-2a]] x 12 wk
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://cloudfront.escholarship.org/dist/prd/content/qt3hb043v4/qt3hb043v4.pdf Meyskens et al. 1995 (SWOG S8642)]
|style="background-color:#1a9851"|Phase III (C)
|Interferon gamma
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/14/1/7.long Kirkwood et al. 1996 (ECOG E1684)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Interferon_alfa-2b_monotherapy|Interferon alfa-2b]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://jco.ascopubs.org/content/16/4/1425.long Pehamberger et al. 1998]
|style="background-color:#1a9851"|Phase III (C)
|[[#Interferon_alfa-2a_monotherapy|Interferon alfa-2a]] x 12 m
|style="background-color:#fc8d59"|Seems to have inferior DFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)12445-X/fulltext Grob et al. 1998]
|style="background-color:#1a9851"|Phase III (C)
|[[#Interferon_alfa-2a_monotherapy|Interferon alfa-2a]] x 18 m
|style="background-color:#fee08b"|Might have inferior OS
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.9.2906 Koops et al. 1998 (EORTC 18832)]
|style="background-color:#1a9851"|Phase III (C)
|Prophylactic ILP
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2444 Kirkwood et al. 2000 (ECOG E1690)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Interferon_alfa-2b_monotherapy|HD-Interferon alfa-2b]] x 12 m
|style="background-color:#fc8d59"|Seems to have inferior RFS
|-
|2. [[#Interferon_alfa-2b_monotherapy|LD-Interferon alfa-2b]] x 24 m
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363881/ Cameron et al. 2001 (The Scottish study)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Interferon_alfa-2b_monotherapy|Interferon alfa-2b]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(01)06068-8/fulltext Cascinelli et al. 2001]
|style="background-color:#1a9851"|Phase III (C)
|[[#Interferon_alfa-2a_monotherapy|Interferon alfa-2a]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.08.071 Sondak et al. 2002]
|style="background-color:#1a9851"|Phase III (C)
|Allogeneic tumor vaccine
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.12.094 Hersey et al. 2002]
|style="background-color:#1a9851"|Phase III (C)
|VMCL
| style="background-color:#fee08b" |Might have inferior OS
|-
|[http://ascopubs.org/doi/10.1200/JCO.2004.03.185 Hancock et al. 2003 (AIM HIGH)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Interferon_alfa-2a_monotherapy|Interferon alfa-2a]] x 24 mo
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(03)00898-0/fulltext Kleeberg et al. 2004 (EORTC 18871/DKG 80-1)]
|style="background-color:#1a9851"|Phase III (C)
|1. [[#Interferon_alfa-2b_monotherapy|Interferon alfa-2b]] x 12 mo<br> 2. Interferon gamma<br> 3. Iscador M
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.20166 Agarwala et al. 2004 (ECOG E1673)]
|style="background-color:#1a9851"|Phase III (C)
|BCG
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67482-X/fulltext Eggermont et al. 2005 (EORTC 18952)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Interferon_alfa-2b_monotherapy|Interferon alfa-2b]]
|style="background-color:#fee08b"|Might have inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61033-8/fulltext Eggermont et al. 2008 (EORTC 18991)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Peginterferon_alfa-2b_monotherapy|Pegylated interferon alfa-2b]]
|style="background-color:#fc8d59"|Seems to have inferior RFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70288-6/fulltext Hansson et al. 2011 (Nordic IFN trial)]
|style="background-color:#1a9851"|Phase III (C)
|1. [[#Interferon_alfa-2b_monotherapy|Interferon alfa-2b]] x 12 mo<br> 2. [[#Interferon_alfa-2b_monotherapy|Interferon alfa-2b]] x 24 mo
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70110-X/fulltext Corrie et al. 2014 (AVAST-M)]
|style="background-color:#1a9851"|Phase III (C)
|Bevacizumab
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684/ Agarwala et al. 2017 (ECOG-ACRIN E1697)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Interferon_alfa-2b_monotherapy|Interferon alfa-2b]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''No treatment after primary resection.''
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
===References===
# Eilber FR, Morton DL, Holmes EC, Sparks FC, Ramming KP. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med. 1976 Jan 29;294(5):237-40. [https://www.nejm.org/doi/full/10.1056/NEJM197601292940501 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1244548 PubMed]
# Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J, De Marsillac J, Ikonopisov RL, Kiss B, Lejeune F, MacKie R, Madej G, Mulder H, Mechl Z, Milton GW, Morabito A, Peter H, Priario J, Paul E, Rumke P, Sertoli R, Tomin R. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982 Oct 7;307(15):913-6. [https://www.nejm.org/doi/full/10.1056/NEJM198210073071503 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7050717 PubMed]
# Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, Paterson AH, Prentice R, Silver HK, Willan AR, Wilson K, Zee B. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1991 May;9(5):729-35. [http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.5.729 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2016615 PubMed]
# '''SWOG S8049:''' Meyskens FL Jr, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, Samlowski W, Balcerzak SP, Rector DJ, Noyes RD, Costanzi JJ. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct;12(10):2060-5. [http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.10.2060 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7931474 PubMed]
# Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, Kugler J, Rodrigue LJ. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995 Nov;13(11):2776-83. [http://ascopubs.org/doi/10.1200/JCO.1995.13.11.2776 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7595738 PubMed]
# '''SWOG S8642:''' Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3. [https://cloudfront.escholarship.org/dist/prd/content/qt3hb043v4/qt3hb043v4.pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7473820 PubMed]
# '''ECOG E1684:''' Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7-17. [http://jco.ascopubs.org/content/14/1/7.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8558223 PubMed]
# Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Auböck J, Fritsch P, Kerl H, Wolff K; Austrian Malignant Melanoma Cooperative Group. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol. 1998 Apr;16(4):1425-9. [http://jco.ascopubs.org/content/16/4/1425.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9552047 PubMed]
# Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ; French Cooperative Group on Melanoma. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet. 1998 Jun 27;351(9120):1905-10. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)12445-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9654256 PubMed]
# '''EORTC 18832:''' Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Göhl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ; European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol. 1998 Sep;16(9):2906-12. [http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.9.2906 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9738557 PubMed]
# '''ECOG E1690:''' Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun;18(12):2444-58. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2444 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10856105 PubMed]
# Cameron DA, Cornbleet MC, Mackie RM, Hunter JA, Gore M, Hancock B, Smyth JF; Scottish Melanoma Group. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer. 2001 May 4;84(9):1146-9. [https://www.nature.com/bjc/journal/v84/n9/full/6691623a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363881/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/11379605 PubMed]
# Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001 Sep 15;358(9285):866-9. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(01)06068-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11567700 PubMed]
# Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002 Apr 15;20(8):2058-66. [http://ascopubs.org/doi/full/10.1200/JCO.2002.08.071 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11956266 PubMed]
# Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol. 2002 Oct 15;20(20):4181-90. [http://ascopubs.org/doi/full/10.1200/JCO.2002.12.094 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12377961 PubMed]
# '''AIM HIGH:''' Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004 Jan 1;22(1):53-61. Epub 2003 Dec 9. [http://ascopubs.org/doi/10.1200/JCO.2004.03.185 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14665609 PubMed]
# '''EORTC 18871/DKG 80-1:''' Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004 Feb;40(3):390-402. [https://www.ejcancer.com/article/S0959-8049(03)00898-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14746858 PubMed]
# '''ECOG E1673:''' Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15;100(8):1692-8. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.20166 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15073858 PubMed]
# '''EORTC 18952:''' Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005 Oct 1;366(9492):1189-96. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67482-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16198768 PubMed]
## '''Update:''' Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer. 2016 Mar;55:111-21. [https://www.ejcancer.com/article/S0959-8049(15)01044-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26790144 PubMed]
# '''EORTC 18991:''' Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-26. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61033-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18620949 PubMed]
## '''Update:''' Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012 Nov 1;30(31):3810-8. Epub 2012 Sep 24. [http://jco.ascopubs.org/content/30/31/3810.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23008300 PubMed]
# '''Nordic IFN trial:''' Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 2011 Feb;12(2):144-52. Epub 2011 Jan 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70288-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21256809 PubMed]
# '''AVAST-M:''' Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 2014 May;15(6):620-30. Epub 2014 Apr 15. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Lancet Oncol. 2014 Jun;15(7):e253. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70110-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24745696 PubMed]
# '''ECOG-ACRIN E1697:''' Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM. Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10;35(8):885-892. Epub 2017 Jan 30. [http://ascopubs.org/doi/full/10.1200/JCO.2016.70.2951 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28135150 PubMed]

==Peginterferon alfa-2b monotherapy {{#subobject:42f282|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:934e7d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61033-8/fulltext Eggermont et al. 2008 (EORTC 18991)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior RFS
|-
|}
''Patients enrolled in EORTC 18991 had resected stage III melanoma.''
====Preceding treatment====
*[[Surgery#Melanoma_surgery|Surgery]]
====Immunotherapy====
*[[Peginterferon alfa-2b (Sylatron)]] as follows:
**Weeks 1 to 8: 6 mcg/kg SC once per week
**Week 9 onwards: 3 mcg/kg SC once per week

'''Given for up to 5 years of therapy if [[performance status|ECOG performance status]] remained 0 or 1'''

===References===
# '''EORTC 18991:''' Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-26. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61033-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18620949 PubMed]
## '''Update:''' Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012 Nov 1;30(31):3810-8. Epub 2012 Sep 24. [http://jco.ascopubs.org/content/30/31/3810.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23008300 PubMed]

==Pembrolizumab monotherapy {{#subobject:0a3e71|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bd92fe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1802357 Eggermont et al. 2018 (EORTC 1325)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Placebo|Placebo]]
|style="background-color:#1a9850"|Superior RFS
|-
|}
====Preceding treatment====
*[[Surgery#Complete_regional_lymphadenectomy|Complete regional lymphadenectomy]], within 13 weeks
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1

'''21-day cycle for 18 cycles'''

===References===
# '''EORTC 1325:''' Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018 May 10;378(19):1789-1801. Epub 2018 Apr 15. [https://www.nejm.org/doi/10.1056/NEJMoa1802357 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29658430 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198011133032003 Spitler & Sagabiel 1980]
|style="background-color:#1a9851"|Phase III (C)
|Levamisole
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://insights.ovid.com/pubmed?pmid=12477996 Markovic et al. 2002]
|style="background-color:#1a9851"|Phase III (C)
|Megestrol acetate
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70122-1/fulltext Eggermont et al. 2015 (EORTC 18071)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Ipilimumab_monotherapy|Ipilimumab]]
|style="background-color:#d73027"|Inferior OS (*)
|style="background-color:#eeee01"|Similar HRQoL
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669592/ Lawson et al. 2015 (ECOG-ACRIN E4697)]
|style="background-color:#1a9851"|Phase III (C)
|1. GM-CSF<br> 2. GM-CSF & Peptide vaccine<br> 3. Peptide vaccine
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa1802357 Eggermont et al. 2018 (EORTC 1325)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
|style="background-color:#d73027"|Inferior RFS
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30254-7/fulltext Dreno et al. 2018 (DERMA)]
|style="background-color:#1a9851"|Phase III (C)
|MAGE-A3 antigen
| style="background-color:#ffffbf" |Seems not superior
|
|-
|}
''No active antineoplastic treatment after primary resection. Placed here because one or more randomized clinical trials included a placebo in this disease context. Efficacy in EORTC 18071 is based on the 2016 update. While there was a statistically significant difference in EORTC QLC-C30 scores in EORTC 18071 (in favor of placebo), this difference did not meet the pre-determined threshold for clinically relevance.''
====Preceding treatment====
*Spitler & Sagabiel 1980: [[Surgery#Melanoma_surgery|Surgery]]
*EORTC 18071: [[Surgery#Complete_regional_lymphadenectomy|Complete regional lymphadenectomy]], within 12 weeks
*ECOG-ACRIN E4697: [[Surgery#Melanoma_surgery|Complete resection]], within 16 weeks
*EORTC 1325: [[Surgery#Complete_regional_lymphadenectomy|Complete regional lymphadenectomy]], within 13 weeks
===References===
# Spitler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med. 1980 Nov 13;303(20):1143-7. [https://www.nejm.org/doi/full/10.1056/NEJM198011133032003 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6999349 PubMed]
# Markovic S, Suman VJ, Dalton RJ, Woods JE, Fitzgibbons RJ Jr, Wold LE, Buckner JC, Kugler JW, Mailliard JA, Rowland KM, Krook JE, Brown DW, Tirona MT, Creagan ET. Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma. Am J Clin Oncol. 2002 Dec;25(6):552-6. [https://insights.ovid.com/pubmed?pmid=12477996 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12477996 PubMed]
# '''EORTC 18071:''' Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 May;16(5):522-30. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70122-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25840693 PubMed]
## '''Correction:''' Eggermont AM, Chiarion-Sileni V, Grob JJ. Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):e262. Epub 2015 May 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70271-8/fulltext link to correction] [https://www.ncbi.nlm.nih.gov/pubmed/26065611 PubMed]
## '''Update:''' Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016 Nov 10;375(19):1845-1855. Epub 2016 Oct 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1611299 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27717298 PubMed]
## '''HRQoL analysis:''' Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bottomley A, Kotapati S, de Pril V, Testori A, Eggermont AM. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017 Mar;18(3):393-403. Epub 2017 Feb 3. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636622/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28162999 PubMed]
# '''ECOG-ACRIN E4697:''' Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, Kirkwood JM. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network cancer research group (E4697). J Clin Oncol. 2015 Dec 1;33(34):4066-76. Epub 2015 Sep 8. [http://ascopubs.org/doi/full/10.1200/JCO.2015.62.0500 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669592/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26351350 PubMed]
# '''EORTC 1325:''' Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018 May 10;378(19):1789-1801. Epub 2018 Apr 15. [https://www.nejm.org/doi/10.1056/NEJMoa1802357 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29658430 PubMed]
# '''DERMA:''' Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Jul;19(7):916-929. Epub 2018 Jun 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30254-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29908991 PubMed]

=Local therapy=
==Talimogene laherparepvec monotherapy {{#subobject:PYR1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:PYV1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/33/25/2780.long Andtbacka et al. 2015]
|style="background-color:#1a9851"|Phase III (E)
|GM-CSF
|style="background-color:#1a9850"|Superior DRR
|-
|}
''Talimogene laherparepvec was injected directly into unresectable cutaneous, subcutaneous, and nodal melanoma lesions.''
====Therapy====
*[[Talimogene laherparepvec (Imlygic)]] as follows:
**Initially: 10<sup>6</sup> pfu/mL (to seroconvert HSV-seronegative patients) SC intralesional injection once on day 1, then 10<sup>8</sup> pfu/mL SC intralesional injection once on day 22
**Thereafter: 10<sup>8</sup> pfu/mL SC intralesional injection once every 2 weeks.
**Total volume given per treatment session was up to 4.0 mL. "Injected volume per lesion ranged from 0.1 mL for lesions less than 0.5 cm to 4.0 mL for lesions greater than 5 cm in longest diameter."

'''Generally given for at least 24 weeks. Treatment continued until progression of disease, unacceptable toxicity, lack of response by 12 months, or disappearance of all injectable lesions.''' 

''Patients with stable or responding disease after 1 year of therapy could continue treatment for another 6 months.''

===References===
<!-- Presented in part at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013, and 50th ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014. -->
# Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015 Sep 1;33(25):2780-8. [http://jco.ascopubs.org/content/33/25/2780.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26014293 PubMed]

=Metastatic or unresectable disease=

==ABC {{#subobject:ddf2d4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ABC: '''<u>A</u>'''braxane (Paclitaxel nanoparticle albumin-bound), '''<u>B</u>'''evacizumab, '''<u>C</u>'''arboplatin

===Regimen {{#subobject:318c66|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089063/ Kottschade et al. 2013 (N0775)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Temozolomide_.26_Bevacizumab|Temozolomide & Bevacizumab]]
|style="background-color:#91cf60"|Seems to have superior PFS6
|-
|}
''The doses listed here are the amended starting doses.''
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1

'''28-day cycles'''

===References===
<!-- This study was presented at the American Society for Clinical Oncology 2011 Annual Meeting, June 3 to 7, Chicago, Illinois, as a poster discussion. -->
# Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML, Markovic SN. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer. 2013 Feb 1;119(3):586-92. Epub 2012 Aug 22. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.27760/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089063/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22915053 PubMed]

==Carboplatin & Paclitaxel {{#subobject:610571|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CP: '''<u>C</u>'''arboplatin & '''<u>P</u>'''aclitaxel
<br>PC: '''<u>P</u>'''aclitaxel & '''<u>C</u>'''arboplatin
===Variant #1, AUC 2/100 {{#subobject:5edf1c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.21611/full Rao et al. 2006]
|style="background-color:#ffffbe"|Retrospective
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV once per day on days 1, 8, 15
*[[Paclitaxel (Taxol)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #2, AUC 6/175 {{#subobject:06b48b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70076-8/fulltext Weber et al. 2015 (CheckMate 037)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy_2|Nivolumab]]
|style="background-color:#d73027"|Inferior ORR (*)
|-
|}
''Note: this study did not meet the co-primary endpoint of OS.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #3, AUC 6/225 x 4, then AUC 5/175 {{#subobject:6a83f2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/27/17/2823.long Hauschild et al. 2009]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Paclitaxel, Sorafenib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878104/ Flaherty et al. 2013 (ECOG E2603)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin, Paclitaxel, Sorafenib
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] as follows:
**Cycles 1 to 4: AUC 6 IV over 30 minutes once on day 1, '''given second'''
**Cycle 5 onwards: AUC 5 IV over 30 minutes once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] as follows:
**Cycles 1 to 4: 225 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''
**Cycle 5 onwards: 175 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for up to 10 cycles, until progression of disease, or unacceptable toxicity'''

===Variant #4, 200/100, 6 out of 8 weeks {{#subobject:64b1c2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://insights.ovid.com/pubmed?pmid=14512795 Zimpfer-Rechner et al. 2003]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Paclitaxel_monotherapy|Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.''
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] 200 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36
*[[Paclitaxel (Taxol)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36

'''8-week cycles'''

===References===
# Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, Hauschild A, Schadendorf D. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003 Oct;13(5):531-6. [https://insights.ovid.com/pubmed?pmid=14512795 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14512795 PubMed]
# '''Retrospective:''' Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006 Jan 15;106(2):375-82. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.21611 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16342250 PubMed]
<!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL. -->
# Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10;27(17):2823-30. Epub 2009 Apr 6. [http://jco.ascopubs.org/content/27/17/2823.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19349552 PubMed]
# '''ECOG E2603:''' Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20;31(3):373-9. Epub 2012 Dec 17. [http://jco.ascopubs.org/content/31/3/373.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878104/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23248256 PubMed]
# '''CheckMate 037:''' Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-84. Epub 2015 Mar 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70076-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25795410 PubMed]
## '''Update:''' Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018 Feb 1;36(4):383-390. Epub 2017 Jul 3. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.8023 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28671856 PubMed]

==Carboplatin & nab-Paclitaxel {{#subobject:a013af|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d78d72|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116030/ Kottschade et al. 2011 (N057E1)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV once per day on days 1, 8, 15, '''given second'''
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, '''given first'''

====Supportive medications====
*"All patients received standard supportive care, including antiemetics, antibiotics, blood/platelet transfusions, erythropoietin, and colony-stimulating factors at the discretion of the treating physician."

'''28-day cycle for up to 8 cycles;''' patients without progressive disease or excessive toxicity could receive additional therapy per physician discretion

===References===
# '''N057E1:''' Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer. 2011 Apr 15;117(8):1704-10. Epub 2010 Nov 8. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.25659/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116030/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21472717 PubMed]

==Cisplatin & Dacarbazine {{#subobject:1c1243|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:fc0483|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/6/1600.long Ridolfi et al. 2002]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Dacarbazine.2C_IL-2.2C_IFN_alfa-2b_.2B.2F-_Carmustine|Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Dacarbazine (DTIC)]] 800 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

===References===
# Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7. [http://jco.ascopubs.org/content/20/6/1600.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11896110 PubMed]

==Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine {{#subobject:d23e47|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a3dd35|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/6/1600.long Ridolfi et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin.2C_Dacarbazine_.2B.2F-_Carmustine|Cisplatin, Dacarbazine +/- Carmustine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Dacarbazine (DTIC)]] 800 mg/m<sup>2</sup> IV once on day 1
*Optional: [[Carmustine (BiCNU)]] 100 mg/m<sup>2</sup> (note: in Ridolfi et al. 2002, in contrast to the treatment text, figure 1 lists a dosage of 150 mg/m<sup>2</sup>) IV once on day 1
*[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] 4,500,000 units/m<sup>2</sup> (Ridolfi et al. 2002 did not clearly specify the frequency and whether this dose was per day or total) SC on days 3 to 5, 8 to 12
*[[Interferon alfa-2b (Intron-A)]] 3,000,000 units/m<sup>2</sup> (Ridolfi et al. 2002 did not clearly specify the frequency and whether this dose was per day or total) IM on days 3 to 5 of week 1, then 3 times per week on all later weeks

'''21-day cycle for 6 cycles'''

===References===
# Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7. [http://jco.ascopubs.org/content/20/6/1600.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11896110 PubMed]

==Cisplatin, Dacarbazine, Paclitaxel {{#subobject:12c753|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9b0171|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2009&issue=10000&article=00011&type=abstract Papadopoulos et al. 2009]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: cycle length is not specified in the abstract. This is the suggested phase II dosing.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Dacarbazine (DTIC)]] 800 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''Continued indefinitely'''

===References===
# Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma. Am J Clin Oncol. 2009 Oct;32(5):509-14. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2009&issue=10000&article=00011&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19506454 PubMed]

==CVD (Vinblastine) {{#subobject:435c97|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CVD: '''<u>C</u>'''isplatin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine
===Variant #1, 20/1.2/800 {{#subobject:e9c736|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645104/ Atkins et al. 2008 (ECOG E3695)]
|style="background-color:#1a9851"|Phase III (C)
|[[#CVD.2C_IL-2.2C_IFN_alfa-2b_-_sequential_biochemotherapy|Sequential biochemotherapy]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 4, '''given first'''
*[[Vinblastine (Velban)]] 1.2 mg/m<sup>2</sup> IV push once per day on days 1 to 4, '''given second'''
*[[Dacarbazine (DTIC)]] 800 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given third'''

====Supportive medications====
*[[:Category:Emesis_prevention|Antiemetics]] 
*[[Dexamethasone (Decadron)]]

'''21-day cycle for up to 4 cycles'''

===Variant #2, 20/1.6/800 {{#subobject:49a6f8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19891115)64:10%3C2024::AID-CNCR2820641010%3E3.0.CO;2-V Legha et al. 1989]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 2 to 5
*[[Vinblastine (Velban)]] 1.6 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Dacarbazine (DTIC)]] 800 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #3, 20/2/800 {{#subobject:353d3a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/8/2045.long Eton et al. 2002]
|style="background-color:#1a9851"|Phase III (C)
|[[#CVD.2C_IL-2.2C_IFN_alfa-2b_-_sequential_biochemotherapy|Sequential biochemotherapy]]
|style="background-color:#d73027"|Inferior TTP
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Vinblastine (Velban)]] 2 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Dacarbazine (DTIC)]] 800 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 10 cycles'''

===References===
# Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989 Nov 15;64(10):2024-9. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19891115)64:10%3C2024::AID-CNCR2820641010%3E3.0.CO;2-V link to original] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2804890 PubMed]
# Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15;20(8):2045-52. [http://jco.ascopubs.org/content/20/8/2045.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11956264 PubMed] content property of [http://hemonc.org HemOnc.org]
# '''ECOG E3695:''' Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10;26(35):5748-54. Epub 2008 Nov 10. [http://jco.ascopubs.org/content/26/35/5748.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645104/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19001327 PubMed]

==CVD (Vindesine) {{#subobject:97b161|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CVD: '''<u>C</u>'''isplatin, '''<u>V</u>'''indesine, '''<u>D</u>'''acarbazine
===Regimen {{#subobject:6b20de|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(98)00068-9/fulltext Jungnelius et al. 1998]
|style="background-color:#1a9851"|Phase III (E)
|Dacarbazine & Vindesine
| style="background-color:#1a9850" |Superior TTP
|-
|[https://academic.oup.com/annonc/article/17/4/571/247765 Bajetta et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|Biochemotherapy
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Vindesine (Eldisine)]] 2.5 mg/m<sup>2</sup> IV once on day 1
*[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycles'''

===References===
# Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U, Ingvar C, Malmström P, Andersson R, Karlsson M, Willman K, Wist E, Bjelkengren G, Westberg R. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma: a randomised phase III trial. Eur J Cancer. 1998 Aug;34(9):1368-74. [https://www.ejcancer.com/article/S0959-8049(98)00068-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9849419 PubMed]
# Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS, Formisano B, Cascinelli N. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol. 2006 Apr;17(4):571-7. Epub 2006 Feb 9. [https://academic.oup.com/annonc/article/17/4/571/247765 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16469753 PubMed]

==CVD, IL-2, IFN alfa-2b - sequential biochemotherapy {{#subobject:53ae36|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CVD, IL-2, IFN alfa-2b: '''<u>C</u>'''isplatin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine, high-dose '''<u>I</u>'''nter'''<u>L</u>'''eukin-'''<u>2</u>''', '''<u>I</u>'''nter'''<u>F</u>'''ero'''<u>N</u>''' alfa-2b
<br>bioCT: '''<u>bioC</u>'''hemo'''<u>T</u>'''herapy
===Example orders===
*[[Example orders for CVD, IL-2, IFN alfa-2b - sequential biochemotherapy in melanoma]]

===Variant #1 {{#subobject:a7741a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://clincancerres.aacrjournals.org/content/6/6/2201.long McDermott et al. 2000]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645104/ Atkins et al. 2008 (ECOG E3695)]
|style="background-color:#1a9851"|Phase III (E)
|[[#CVD_.28Vinblastine.29|CVD]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
====Chemoimmunotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 4, '''given first'''
*[[Vinblastine (Velban)]] 1.2 mg/m<sup>2</sup> IV push once per day on days 1 to 4, '''given second'''
*[[Dacarbazine (DTIC)]] 800 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given third'''
*[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] 9,000,000 units/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36,000,000 units/m<sup>2</sup>)
*[[Interferon alfa-2b (Intron-A)]] 5,000,000 units/m<sup>2</sup> SC once per day on days 1 to 5, 8, 10, 12; ''doses on days 8, 10, 12 are given as outpatient doses''

====Supportive medications====
*All antihypertensive therapy discontinued at least 24 hours before each cycle
*[[Cephalexin (Keflex)]] or [[Ciprofloxacin (Cipro)]] 250 mg PO twice per day on days 1 to 14
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 7 to 16, or until ANC greater than 10,000/uL
*[[Ondansetron (Zofran)]] 32 mg IV once per day
*[[Lorazepam (Ativan)]] 1 mg IV or PO every 6 hours
*[[Acetaminophen (Tylenol)]] 650 mg PO every 6 hours
*[[Ranitidine (Zantac)]] 150 mg PO every 12 hours
*[[Hydroxyzine (Atarax)]] 25 to 50 mg PO or [[Diphenhydramine (Benadryl)]] 25 mg PO every 6 hours for pruritis
*[[Meperidine (Demerol)]] 25 to 50 mg IV every 3 hours for chills and rigors
*Antidiarrheals & anxiolytics as needed

'''21-day cycle for up to 4 cycles'''

===Variant #2 {{#subobject:118ce0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/8/2045.long Eton et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|[[#CVD_.28Vinblastine.29|CVD]]
|style="background-color:#1a9850"|Superior TTP
|-
|}
====Chemoimmunotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 4, 22 to 25
*[[Vinblastine (Velban)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 to 4, 22 to 25
*[[Dacarbazine (DTIC)]] 800 mg/m<sup>2</sup> IV once per day on days 1 & 22
*[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] 9,000,000 units/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on days 5, 17, 26 (total dose per cycle: 108,000,000 units/m<sup>2</sup>)
*[[Interferon alfa-2b (Intron-A)]] 5,000,000 units/m<sup>2</sup> SC once per day on days 5 to 9, 17 to 21, 26 to 30

'''42-day cycle for up to 5 cycles'''

===Variant #3 {{#subobject:09d9da|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1998.16.5.1752 Legha et al. 1998]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemoimmunotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Vinblastine (Velban)]] 1.6 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Dacarbazine (DTIC)]] 800 mg/m<sup>2</sup> IV once on day 1
*[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] 9,000,000 units/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36,000,000 units/m<sup>2</sup>)
*[[Interferon alfa-2b (Intron-A)]] 5,000,000 units/m<sup>2</sup> SC once per day on days 1 to 5

'''21-day cycle for 6 cycles'''

===References===
# Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998 May;16(5):1752-9. [http://ascopubs.org/doi/full/10.1200/JCO.1998.16.5.1752 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9586888 PubMed]
# McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res. 2000 Jun;6(6):2201-8. [http://clincancerres.aacrjournals.org/content/6/6/2201.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10873069 PubMed]
# Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15;20(8):2045-52. [http://jco.ascopubs.org/content/20/8/2045.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11956264 PubMed]
# '''ECOG E3695:''' Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10;26(35):5748-54. Epub 2008 Nov 10. [http://jco.ascopubs.org/content/26/35/5748.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645104/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19001327 PubMed]

==Dacarbazine monotherapy {{#subobject:d3599b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Dacarbazine (DTIC) in melanoma]]
===Variant #1, 850 mg/m<sup>2</sup> q3wk {{#subobject:b6dcb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/7459898 Pritchard et al. 1980]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1104621 Robert et al. 2011 (CA184-024)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Dacarbazine_.26_Ipilimumab|Dacarbazine & Ipilimumab]]
|style="background-color:#d73027"|Inferior OS
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Dacarbazine (DTIC)]] 850 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 cycles'''

===Variant #2, 850 mg/m<sup>2</sup> q4wk {{#subobject:954862|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/17/4/563/247556 Schadendorf et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|Dendritic cell vaccine
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Dacarbazine (DTIC)]] 850 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles'''

===Variant #3, 900 mg/m<sup>2</sup> q3wk {{#subobject:a17084|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598549/ Daponte et al. 2013 (SICOG 0109)]
|style="background-color:#1a9851"|Phase III (C)
|1. Dacarbazine & Fotemustine<br> 2. Dacarbazine & IFN<br> 3. Dacarbazine, Fotemustine, IFN
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Dacarbazine (DTIC)]] 900 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #4, 1000 mg/m<sup>2</sup> q3wk {{#subobject:bede4c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/jco.1999.17.9.2745 Chapman et al. 1999]
|style="background-color:#1a9851"|Phase III (C)
|Dartmouth regimen
| style="background-color:#fee08b" |Might have inferior ORR
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303777/ Bedikian et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|DHA-paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(11)00309-1/fulltext Patel et al. 2011 (EORTC 18032)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Temozolomide_monotherapy|Temozolomide]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549296/ Chapman et al. 2011 (BRIM-3)]
|style="background-color:#1a9851"|Phase III (C)
|[[Melanoma,_BRAF-mutated#Vemurafenib_monotherapy|Vemurafenib]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60868-X/fulltext Hauschild et al. 2012 (BREAK-3)]
|style="background-color:#1a9851"|Phase III (C)
|[[Melanoma,_BRAF-mutated#Dabrafenib_monotherapy|Dabrafenib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1203421 Flaherty et al. 2012 (METRIC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Melanoma,_BRAF-mutated#Trametinib_monotherapy|Trametinib]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878048/ Ribas et al. 2013 (A3671009)]
|style="background-color:#1a9851"|Phase III (C)
|Tremelimumab
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1412082 Robert et al. 2014 (CheckMate 066)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy_2|Nivolumab]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70076-8/fulltext Weber et al. 2015 (CheckMate 037)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy_2|Nivolumab]]
|style="background-color:#d73027"|Inferior ORR (*)
|-
|[http://annonc.oxfordjournals.org/content/26/11/2267.long Hersh et al. 2015]
|style="background-color:#1a9851"|Phase III (C)
|nab-Paclitaxel
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30180-8/fulltext Dummer et al. 2017 (NEMO)]
|style="background-color:#1a9851"|Phase III (C)
|[[Melanoma,_NRAS-mutated#Binimetinib_monotherapy|Binimetinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652683/ Ugurel et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|Chemosensitivity-directed therapy
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: CheckMate 037 did not meet the co-primary endpoint of OS. Patients in '''BRIM-3''' had a BRAF p.V600E mutation detected. Patients in '''NEMO''' had NRAS mutations.''
====Chemotherapy====
*[[Dacarbazine (DTIC)]] 1000 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #5, 1000 mg/m<sup>2</sup>, split doses, q4wk {{#subobject:3f3475|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/jco.1998.16.5.1743 Falkson et al. 2003]
|style="background-color:#1a9851"|Phase III (C)
|1. DTIC & Interferon<br> 2. DTIC & Tamoxifen<br> 3. DTIC, Interferon, Tamoxifen
|style="background-color:#fc8d59"|Seems to have inferior ORR
|-
|}
====Chemotherapy====
*[[Dacarbazine (DTIC)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 5

'''28-day cycles'''

===Variant #6, 1250 mg/m<sup>2</sup>, split doses, q3wk {{#subobject:4bacb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJM199208203270803 Cocconi et al. 1992]
|style="background-color:#1a9851"|Phase III (C)
|Dacarbazine & Tamoxifen
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://jco.ascopubs.org/content/18/1/158.long Middleton et al. 2000]
|style="background-color:#1a9851"|Phase III (C)
|[[#Temozolomide_monotherapy|Temozolomide]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|}
====Chemotherapy====
*[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV over 20 to 30 minutes once per day on days 1 to 5

'''21-day cycles'''

===Variant #7, 1250 mg/m<sup>2</sup>, split doses, q4wk {{#subobject:f3110c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.04.165 Avril et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|[[#Fotemustine_monotherapy|Fotemustine]]
|style="background-color:#fc8d59"|Seems to have inferior ORR
|-
|}
====Chemotherapy====
*[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV over 20 to 30 minutes once per day on days 1 to 5

'''28-day cycles'''

===Variant #8, 2500 mg/m<sup>2</sup>, split doses, q4wk {{#subobject:ac310c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1984.2.3.164 Luikart et al. 1984]
|style="background-color:#1a9851"|Phase III (C)
|VBD
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 10

'''28-day cycles'''

===References===
# Pritchard KI, Quirt IC, Cowan DH, Osoba D, Kutas GJ. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1123-6. [https://www.ncbi.nlm.nih.gov/pubmed/7459898 PubMed]
# Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol. 1984 Mar;2(3):164-8. [http://ascopubs.org/doi/abs/10.1200/JCO.1984.2.3.164 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6199481 PubMed]
# Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, Lottici R, Papadia F, Sofra MC, Bacchi M. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992 Aug 20;327(8):516-23. [https://www.nejm.org/doi/10.1056/NEJM199208203270803 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1635566 PubMed]
# Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998 May;16(5):1743-51. [http://ascopubs.org/doi/10.1200/jco.1998.16.5.1743 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9586887 PubMed]
# Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999 Sep;17(9):2745-51. [http://ascopubs.org/doi/10.1200/jco.1999.17.9.2745 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10561349 PubMed]
# Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000 Jan;18(1):158-66. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. [http://jco.ascopubs.org/content/18/1/158.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10623706 PubMed]
# Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004 Mar 15;22(6):1118-25. [http://ascopubs.org/doi/full/10.1200/JCO.2004.04.165 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15020614 PubMed]
# Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tüttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler G; DC study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006 Apr;17(4):563-70. Epub 2006 Jan 17. [https://academic.oup.com/annonc/article/17/4/563/247556 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16418308 PubMed]
# Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, Ernstoff M. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011 Apr;22(4):787-93. Epub 2010 Sep 20. [https://academic.oup.com/annonc/article/22/4/787/214568 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303777/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20855467 PubMed]
# '''EORTC 18032:''' Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A; EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011 Jul;47(10):1476-83. Epub 2011 May 18. [https://www.ejcancer.com/article/S0959-8049(11)00309-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21600759 PubMed]
# '''BRIM-3:''' Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16. Epub 2011 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1103782 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549296/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21639808 PubMed]
## '''Update:''' McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar;15(3):323-32. Epub 2014 Feb 7. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382632/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24508103 PubMed]
# '''CA184-024:''' Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. Epub 2011 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1104621 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21639810 PubMed]
## '''Update:''' Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015 Apr 1;33(10):1191-6. Epub 2015 Feb 23. [http://jco.ascopubs.org/content/33/10/1191.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25713437 PubMed]
# '''BREAK-3:''' Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. Epub 2012 Jun 25. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60868-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22735384 PubMed]
# '''METRIC:''' Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. Epub 2012 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1203421 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22663011 PubMed]
<!-- Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2008, and 25th Annual Meeting of the International Society for Biological Therapy of Cancer, Washington, DC, October 2-4, 2010. -->
# '''A3671009:''' Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10;31(5):616-22. Epub 2013 Jan 7. [http://ascopubs.org/doi/full/10.1200/JCO.2012.44.6112 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878048/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23295794 PubMed]
# '''SICOG 0109:''' Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA; Southern Italy Cooperative Oncology Group (SICOG). Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. J Transl Med. 2013 Feb 13;11:38. [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-11-38 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598549/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23402397 PubMed]
# '''CheckMate 066:''' Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320-30. Epub 2014 Nov 16. [https://www.nejm.org/doi/full/10.1056/NEJMoa1412082 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25399552 PubMed]
## '''Update:''' Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2018 Oct 25. [Epub ahead of print] [https://jamanetwork.com/journals/jamaoncology/article-abstract/2707224 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30422243 PubMed]
# '''CheckMate 037:''' Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-84. Epub 2015 Mar 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70076-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25795410 PubMed]
## '''Update:''' Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018 Feb 1;36(4):383-390. Epub 2017 Jul 3. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.8023 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28671856 PubMed]
# Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Ann Oncol. 2015 Nov;26(11):2267-74. Epub 2015 Sep 26. [http://annonc.oxfordjournals.org/content/26/11/2267.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26410620 PubMed]
# '''NEMO:''' Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. Epub 2017 Mar 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30180-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28284557 PubMed]
# Ugurel S, Loquai C, Terheyden P, Schadendorf D, Richtig E, Utikal J, Gutzmer R, Rass K, Sunderkötter C, Stein A, Fluck M, Kaatz M, Trefzer U, Kähler K, Stadler R, Berking C, Höller C, Kerschke L, Edler L, Kopp-Schneider A, Becker JC. Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. Oncotarget. 2017 Jun 27;8(44):76029-76043. eCollection 2017 Sep 29. [http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=18635 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652683/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29100289 PubMed]

==Dacarbazine & Interferon alfa {{#subobject:100004|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bcd593|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363341/ Middleton et al. 2000]
|style="background-color:#1a9851"|Phase III (C)
|DBCT
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363865/ Hauschild et al. 2001]
|style="background-color:#1a9851"|Phase III (C)
|Dacarbazine, IFN alfa, IL-2
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Dacarbazine (DTIC)]]
*[[:Category:Interferons|Interferon alfa]]

===References===
# Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, Thatcher N. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer. 2000 Mar;82(6):1158-62. [https://www.nature.com/articles/6691056 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363341/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/10735499 PubMed]
# Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer. 2001 Apr 20;84(8):1036-42. [https://www.nature.com/articles/6691731 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363865/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/11308250 PubMed]

==Dacarbazine & Ipilimumab {{#subobject:5754a8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7b4884|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1104621 Robert et al. 2011 (CA184-024)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Dacarbazine_monotherapy|Dacarbazine]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemotherapy====
*[[Dacarbazine (DTIC)]] 850 mg/m<sup>2</sup> IV once on day 1
*[[Ipilimumab (Yervoy)]] as follows:
**Cycles 1 to 4: 10 mg/kg IV once on day 1

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*SD or better: [[#Ipilimumab_monotherapy_3|Ipilimumab maintenance]]

===References===
# '''CA184-024:''' Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. Epub 2011 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1104621 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21639810 PubMed]
## '''Update:''' Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015 Apr 1;33(10):1191-6. Epub 2015 Feb 23. [http://jco.ascopubs.org/content/33/10/1191.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25713437 PubMed]

==Docetaxel monotherapy {{#subobject:bd3e54|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:46549|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/7654429 Aamdal et al. 1994]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1

====Supportive medications====
*"No prophylactic treatment with steroids or antihistamines was given."

'''21-day cycles'''

===References===
# Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30A(8):1061-4. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7654429 PubMed]

==Fotemustine monotherapy {{#subobject:92d0c6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ff4f50|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.04.165 Avril et al. 2004]
| style="background-color:#1a9851" |Phase III (E)
|[[#Dacarbazine_monotherapy|Dacarbazine]]
| style="background-color:#91cf60" |Seems to have superior ORR
|-
|}
====Chemotherapy====
*[[Fotemustine (Muphoran)]] as follows:
**Weeks 1 to 3: 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
**Weeks 4 to 8: no treatment
**Week 9 onwards: 100 mg/m<sup>2</sup> IV once on day 1, every 3 weeks

'''8-week induction cycle, then 21-day cycles'''

===References===
# Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004 Mar 15;22(6):1118-25. [http://ascopubs.org/doi/full/10.1200/JCO.2004.04.165 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15020614 PubMed]

==High-dose Interleukin-2 {{#subobject:771c23|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
HD IL-2: '''<u>H</u>'''igh-'''<u>D</u>'''ose '''<u>I</u>'''nter'''<u>L</u>'''eukin-'''<u>2</u>'''
===Example orders===
*[[Example orders for High-dose (HD) IL-2 in melanoma]]

===Regimen {{#subobject:4efbce|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1993.11.10.1969 Sparano et al. 1993]
| style="background-color:#1a9851" |Phase III (C)
|HD IL-2 & IFN alfa-2a
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jamanetwork.com/journals/jama/article-abstract/368156 Rosenberg et al. 1994]
|style="background-color:#91cf61"|Case series
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/17/7/2105.long Atkins et al. 1999]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517182/ Schwartzentruber et al. 2011]
| style="background-color:#1a9851" |Phase III (C)
|HD IL-2 & gp100 vaccine
| style="background-color:#fc8d59" |Seems to have inferior clinical response
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Immunotherapy====
*[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] 600,000 or 720,000 units/kg IV every 8 hours for up to 14 doses per week, on days 1 to 5
**After a 6 to 9 day rest period, another 14 doses per week given over 5 days is given as described above

====Supportive medications====
*Included:
*[[Acetaminophen (Tylenol)]]
*[[Indomethacin (Indocin)]]
*[[Meperidine (Demerol)]]
*[[Ranitidine (Zantac)]]
*[[Cimetidine (Tagamet)]]
*[[Hydroxyzine (Atarax)]]
*[[Diphenhydramine (Benadryl)]]
*Dopamine, phenylephrine, antidiarrheals, antiemetics, anxiolytics, diuretics, and, if needed, antibiotics.

'''6 to 12 weeks per cycle for up to 5 cycles'''

===References===
# Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, Doroshow JH, Aronson FR, Rubinstein LV, Mier JW. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993 Oct;11(10):1969-77. [http://ascopubs.org/doi/abs/10.1200/JCO.1993.11.10.1969 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8410122 PubMed]
# Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994 Mar 23-30;271(12):907-13. [http://jamanetwork.com/journals/jama/article-abstract/368156 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8120958 PubMed]
# Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 Jul;17(7):2105-16. [http://jco.ascopubs.org/content/17/7/2105.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10561265 PubMed]
## '''Update:''' Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S11-4. [https://www.ncbi.nlm.nih.gov/pubmed/10685652 PubMed]
# Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 2;364(22):2119-27. [https://www.nejm.org/doi/full/10.1056/NEJMoa1012863 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517182/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21631324 PubMed]

==Low-dose Interleukin-2 {{#subobject:a2e938|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
LD IL-2: '''<u>L</u>'''ow-'''<u>D</u>'''ose '''<u>I</u>'''nter'''<u>L</u>'''eukin-'''<u>2</u>'''
===Regimen {{#subobject:cbb5b2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
! style="width: 25%" |Study
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
! style="width: 25%" |Comparator
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.20.1.125 Agarwala et al. 2002]
|style="background-color:#1a9851" |Phase III (C)
|LD IL-2 & Histamine
| style="background-color:#d73027" |Inferior OS
|-
|}
====Immunotherapy====
*[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] as follows:
**Weeks 1 & 3: 9,000,000 units SC twice per day on days 1 & 2
**Weeks 2 & 4: 2,000,000 units SC twice per day on days 1 to 5

'''6-week cycles'''
===References===
# Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 1;20(1):125-33. [http://ascopubs.org/doi/full/10.1200/JCO.2002.20.1.125 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11773161 PubMed]

==Imatinib monotherapy {{#subobject:8686d5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:662612|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ Hodi et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
''Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.''
====Starting dose====
*[[Imatinib (Gleevec)]] 400 mg PO once per day

'''Given until disease progression; then proceed to higher dose:'''

====Higher dose====
*[[Imatinib (Gleevec)]] 400 mg PO twice per day

'''Given until disease progression'''

===Variant #2 {{#subobject:d1f61b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ Carvajal et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
''Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.''
====Chemotherapy====
*[[Imatinib (Gleevec)]] 400 mg PO twice per day

'''Given until disease progression'''

===References===
# Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986039/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21642685 PubMed]
# Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. [http://jco.ascopubs.org/content/31/26/3182.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23775962 PubMed]

==Ipilimumab monotherapy {{#subobject:fab3f4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Example orders===
*[[Example orders for Ipilimumab (Yervoy) in melanoma]]

===Variant #1, 3 mg/kg {{#subobject:33786a|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|rowspan=2 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297/ Hodi et al. 2010 (MDX010-20)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Ipilimumab & gp100 peptide vaccine
|style="background-color:#ffffbf"|Seems not superior
|style="background-color:#d3d3d3"|
|-
|2. gp100 peptide vaccine
|style="background-color:#1a9850"|Superior OS
|style="background-color:#d3d3d3"|
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1503093 Robert et al. 2015 (KEYNOTE-006)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Pembrolizumab_monotherapy_2|Pembrolizumab 10 mg/kg q2wks]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d3d3d3"|
|-
|2. [[#Pembrolizumab_monotherapy_2|Pembrolizumab 10 mg/kg q3wks]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#d3d3d3"|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1414428 Postow et al. 2015 (CheckMate 069)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Ipilimumab_.26_Nivolumab|Ipilimumab & Nivolumab]]
|style="background-color:#d73027"|Inferior PFS
|style="background-color:#d3d3d3"|
|-
|rowspan=2 |[https://www.nejm.org/doi/full/10.1056/NEJMoa1504030 Larkin et al. 2015 (CheckMate 067)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Ipilimumab_.26_Nivolumab|Ipilimumab & Nivolumab]]
|style="background-color:#d73027"|Inferior OS (*)
|style="background-color:#eeee01"|Equivalent HRQoL
|-
|2. [[#Nivolumab_monotherapy_2|Nivolumab]]
|style="background-color:#d73027"|Inferior OS (*)
|style="background-color:#eeee01"|Equivalent HRQoL
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30231-0/fulltext Ascierto et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|Ipilimumab 10 mg/kg
|style="background-color:#fc8d59"|Seems to have inferior OS
|style="background-color:#d3d3d3"|
|-
|}
''Note: reported efficacy for CheckMate 067 is based on the 2018 update.''
====Immunotherapy====
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV over 90 minutes once on day 1

'''21-day cycle for 4 cycles'''

===Variant #2, 10 mg/kg {{#subobject:7e975b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2809%2970334-1/fulltext Wolchok et al. 2010]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://annonc.oxfordjournals.org/content/21/8/1712.long O'Day et al. 2010]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70090-6/abstract Margolin et al. 2012]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336189/ Hodi et al. 2014 (ECOG E1608)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Ipilimumab & Sargramostim
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30231-0/fulltext Ascierto et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|Ipilimumab 3 mg/kg
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note: In '''Wolchok et al. 2010''', lower doses including 3 mg/kg (the FDA approved dose) were investigated, but the 10 mg/kg dose was recommended.''
====Immunotherapy====
*[[Ipilimumab (Yervoy)]] 10 mg/kg IV over 90 minutes once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*O'Day et al. 2010 & Margolin et al. 2012: Patients who were clinically stable could proceed to [[#Ipilimumab_monotherapy_3|ipilimumab maintenance]]

===References===
# Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010 Feb;11(2):155-64. Epub 2009 Dec 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2809%2970334-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20004617 PubMed]
# '''MDX010-20:''' Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290. [https://www.nejm.org/doi/full/10.1056/NEJMoa1003466 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20525992 PubMed]
## '''Update:''' McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S; MDX010-20 Investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013 Oct;24(10):2694-8. Epub 2013 Aug 13. [http://annonc.oxfordjournals.org/content/24/10/2694.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23942774 PubMed]
# O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug;21(8):1712-7. Epub 2010 Feb 10. [http://annonc.oxfordjournals.org/content/21/8/1712.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20147741 PubMed]
# Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012 May;13(5):459-65. Epub 2012 Mar 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70090-6/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22456429 PubMed]
# '''ECOG E1608:''' Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 5;312(17):1744-53. [https://jamanetwork.com/journals/jama/fullarticle/1920969 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336189/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25369488 PubMed]
# '''KEYNOTE-006:''' Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32. Epub 2015 Apr 19. [https://www.nejm.org/doi/full/10.1056/NEJMoa1503093 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25891173 PubMed]
## '''Update:''' Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Oct 21;390(10105):1853-1862. Epub 2017 Aug 16. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31601-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28822576 PubMed]
# '''CheckMate 069:''' Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006-17. Epub 2015 Apr 20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1414428 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25891304 PubMed]
## '''Update:''' Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1558-1568. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30366-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27622997 PubMed]
# '''CheckMate 067:''' Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 2;373(1):23-34. Epub 2015 May 31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1504030 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26027431 PubMed]
## '''HRQoL analysis:''' Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017 Sep;82:80-91. Epub 2017 Jun 23. [https://www.ejcancer.com/article/S0959-8049(17)30995-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28651159 PubMed]
## '''Update:''' Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1480-92. Epub 2018 Oct 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30700-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30361170 PubMed]
# Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017 May;18(5):611-622. Epub 2017 Mar 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30231-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28359784 PubMed]

==Ipilimumab & Nivolumab {{#subobject:517ff0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:3a481c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|rowspan=2 |[https://www.nejm.org/doi/full/10.1056/NEJMoa1504030 Larkin et al. 2015 (CheckMate 067)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Ipilimumab_monotherapy_2|Ipilimumab]]
|style="background-color:#1a9850"|Superior OS (*)
|style="background-color:#91cf61"|Equivalent HRQoL
|-
|2. [[#Nivolumab_monotherapy_2|Nivolumab]]
|style="background-color:#1a9850"|Superior PFS
|style="background-color:#91cf61"|Equivalent HRQoL
|-
|}
''Note: reported efficacy for the comparison marked with (*) is based on the 2018 update.''
====Immunotherapy, part 1====
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1
*[[Nivolumab (Opdivo)]] 1 mg/kg IV once on day 1

'''21-day cycle for 4 cycles, followed by:'''

====Immunotherapy, part 2====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
**Notably, on 9/13/16 the [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm FDA recommended] that dosing for this indication be changed to 240 mg with the same schedule based on updated pharmacokinetic data.

'''14-day cycles'''

===Variant #2 {{#subobject:fa55a8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1302369 Wolchok et al. 2013 (CA209-004)]
| style="background-color:#ffffbe" |Phase 1
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1414428 Postow et al. 2015 (CheckMate 069)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Ipilimumab_monotherapy_2|Ipilimumab]]
|style="background-color:#1a9850"|Superior PFS
|}
''These doses were from the cohort deemed by Wolchok et al. 2013 as being "the maximum doses that were associated with an acceptable level of adverse events."''
====Immunotherapy, part 1====
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1, '''given second'''
*[[Nivolumab (Opdivo)]] 1 mg/kg IV once on day 1, '''given first'''

'''21-day cycle for 4 cycles, followed by:'''

====Immunotherapy, part 2====
*[[Nivolumab (Opdivo)]] 1 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Ipilimumab_.26_Nivolumab_2|Ipilimumab & nivolumab maintenance]]

===References===
# '''Phase I:''' Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 Jul 11;369(2):122-33. [https://www.nejm.org/doi/full/10.1056/NEJMoa1302369 link to original article] '''contains verified protocol''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1302369/suppl_file/nejmoa1302369_appendix.pdf link to supplementary appendix] [https://www.ncbi.nlm.nih.gov/pubmed/23724867 PubMed]
# '''CheckMate 069:''' Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006-17. Epub 2015 Apr 20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1414428 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25891304 PubMed]
## '''Update:''' Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1558-1568. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30366-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27622997 PubMed]
# '''CheckMate 067:''' Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 2;373(1):23-34. Epub 2015 May 31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1504030 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26027431 PubMed]
## '''HRQoL analysis:''' Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017 Sep;82:80-91. Epub 2017 Jun 23. [https://www.ejcancer.com/article/S0959-8049(17)30995-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28651159 PubMed]
## '''Update:''' Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1480-92. Epub 2018 Oct 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30700-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30361170 PubMed]

==Ipilimumab, then Nivolumab {{#subobject:184810|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8347ab|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30126-7/fulltext Weber et al. 2016 (CheckMate 064)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Nivolumab.2C_then_Ipilimumab|Nivolumab, then Ipilimumab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Immunotherapy, part 1====
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1

'''21-day cycle for 4 cycles, followed by:'''

====Immunotherapy, part 2====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
**Notably, on 9/13/16 the [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm FDA recommended] that dosing for this indication be changed to 240 mg with the same schedule based on updated pharmacokinetic data.

'''14-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Nivolumab_monotherapy_3|Nivolumab maintenance]]

===References===
# Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):943-55. Epub 2016 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30126-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474305/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27269740 PubMed]

==Nivolumab monotherapy {{#subobject:6a44dd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, limited duration {{#subobject:1ec35|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837092/ Weber et al. 2013]
|style="background-color:#ffffbe"|Phase I
|-
|}
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
**Notably, on 9/13/16 the [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm FDA recommended] that dosing for this indication be changed to 240 mg with the same schedule based on updated pharmacokinetic data.

'''14-day cycle for 12 cycles'''
====Subsequent treatment====
*[[#Nivolumab_monotherapy_3|Nivolumab maintenance]]

===Variant #2, indefinite {{#subobject:722e51|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1412082 Robert et al. 2014 (CheckMate 066)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Dacarbazine_monotherapy|Dacarbazine]]
|style="background-color:#1a9850"|Superior OS
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70076-8/fulltext Weber et al. 2015 (CheckMate 037)]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#Dacarbazine_monotherapy|Dacarbazine]]<br> 2. [[#Carboplatin_.26_Paclitaxel|Carboplatin & Paclitaxel]]
|style="background-color:#1a9850"|Superior ORR (*)
|
|-
|rowspan=2 |[https://www.nejm.org/doi/full/10.1056/NEJMoa1504030 Larkin et al. 2015 (CheckMate 067)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Ipilimumab_monotherapy_2|Ipilimumab]]
|style="background-color:#1a9850"|Superior OS (*)
|style="background-color:#91cf61"|Equivalent HRQoL
|-
|2. [[#Ipilimumab_.26_Nivolumab|Ipilimumab & Nivolumab]]
|style="background-color:#d73027"|Inferior PFS
|style="background-color:#91cf61"|Equivalent HRQoL
|-
|}
''Note: CheckMate 037 did not meet the co-primary endpoint of OS. Reported efficacy for the CheckMate 067 comparison marked with (*) is based on the 2018 update.''
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
**Notably, on 9/13/16 the [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm FDA recommended] that dosing for this indication be changed to 240 mg with the same schedule based on updated pharmacokinetic data.

'''14-day cycles'''

===References===
# '''Phase I:''' Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec 1;31(34):4311-8. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837092/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24145345 PubMed]
# '''CheckMate 066:''' Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320-30. Epub 2014 Nov 16. [https://www.nejm.org/doi/full/10.1056/NEJMoa1412082 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25399552 PubMed]
## '''Update:''' Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2018 Oct 25. [Epub ahead of print] [https://jamanetwork.com/journals/jamaoncology/article-abstract/2707224 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30422243 PubMed]
# '''CheckMate 037:''' Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-84. Epub 2015 Mar 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70076-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25795410 PubMed]
## '''Update:''' Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018 Feb 1;36(4):383-390. Epub 2017 Jul 3. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.8023 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28671856 PubMed]
# '''CheckMate 067:''' Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 2;373(1):23-34. Epub 2015 May 31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1504030 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26027431 PubMed]
## '''HRQoL analysis:''' Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017 Sep;82:80-91. Epub 2017 Jun 23. [https://www.ejcancer.com/article/S0959-8049(17)30995-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28651159 PubMed]
## '''Update:''' Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1480-92. Epub 2018 Oct 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30700-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30361170 PubMed]

==Nivolumab, then Ipilimumab {{#subobject:1145b9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:61d1da|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30126-7/fulltext Weber et al. 2016 (CheckMate 064)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Ipilimumab.2C_then_Nivolumab|Ipilimumab, then Nivolumab]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Immunotherapy, part 1====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
**Notably, on 9/13/16 the [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm FDA recommended] that dosing for this indication be changed to 240 mg with the same schedule based on updated pharmacokinetic data.

'''14-day cycle for 6 cycles, followed by:'''

====Immunotherapy, part 2====
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Nivolumab_monotherapy_3|Nivolumab maintenance]]

===References===
# Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):943-55. Epub 2016 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30126-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474305/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27269740 PubMed]

==Paclitaxel monotherapy {{#subobject:bfd5b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Paclitaxel (Taxol) in melanoma]]

===Variant #1, 80 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:d13282|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/9/1211.long O'Day et al. 2013 (SYMMETRY)]
|style="background-color:#1a9851"|Phase III (C)
|Elesclomol & Paclitaxel
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.28635 Hamid et al. 2014]
|style="background-color:#1a9851"|Phase III (C)
|Tasisulam
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This was the control arm of SYMMETRY, which was a negative study. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #2, 175 mg/m<sup>2</sup> q3wk {{#subobject:100b77|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1203421 Flaherty et al. 2012 (METRIC)]
|style="background-color:#1a9851"|Phase III (C)
|[[Melanoma,_BRAF-mutated#Trametinib_monotherapy|Trametinib]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
''This was a therapy option for patients in the control arm of METRIC. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #3, 250 mg/m<sup>2</sup> q3wk {{#subobject:283bc4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19900601)65:11%3C2478::AID-CNCR2820651114%3E3.0.CO;2-S Legha et al. 1990]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 250 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

'''21-day cycles'''

===References===
# Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer. 1990 Jun 1;65(11):2478-81. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19900601)65:11%3C2478::AID-CNCR2820651114%3E3.0.CO;2-S link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1970948 PubMed]
# '''METRIC:''' Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. Epub 2012 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1203421 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22663011 PubMed]
# '''SYMMETRY:''' O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013 Mar 20;31(9):1211-8. Epub 2013 Feb 11. [http://jco.ascopubs.org/content/31/9/1211.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23401447 PubMed]
# Hamid O, Ilaria R Jr, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, Grob JJ. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. Cancer. 2014 Jul 1;120(13):2016-24. Epub 2014 Mar 26. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.28635 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24676877 PubMed]

==Paclitaxel, nanoparticle albumin-bound monotherapy {{#subobject:1748f5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:df0a74|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.24720/abstract Hersh et al. 2012]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://annonc.oxfordjournals.org/content/26/11/2267.long Hersh et al. 2015]
|style="background-color:#1a9851"|Phase III (E)
|[[#Dacarbazine_monotherapy|Dacarbazine]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 150 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #2 {{#subobject:f13d6e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.24720/abstract Hersh et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this dose was intended for previously treated patients.''
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010 Jan 1;116(1):155-63. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.24720/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19877111 PubMed]
# Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Ann Oncol. 2015 Nov;26(11):2267-74. Epub 2015 Sep 26. [http://annonc.oxfordjournals.org/content/26/11/2267.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26410620 PubMed]

==Pembrolizumab monotherapy {{#subobject:78d8cc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 2 mg/kg q3wk {{#subobject:25a9fe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126516/ Hamid et al. 2013 (KEYNOTE-001)]
| style="background-color:#91cf61" |Phase I, >20 pts
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00083-2/fulltext Ribas et al. 2015 (KEYNOTE-002)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|Investigator-choice of:<br> 1. [[#Carboplatin_.26_Paclitaxel|Carboplatin & Paclitaxel]]<br> 2. [[#Dacarbazine_monotherapy|Dacarbazine]]<br> 3. [[#Paclitaxel_monotherapy|Paclitaxel]]<br> 4. [[#Temozolomide_monotherapy|Temozolomide]]
|style="background-color:#1a9850"|Superior PFS
|-
|5. Pembrolizumab 10 mg/kg q3wk
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 2 mg/kg IV over 30 minutes once on day 1

'''21-day cycles'''

===Variant #2, 10 mg/kg q2wk {{#subobject:2829cd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126516/ Hamid et al. 2013 (KEYNOTE-001)]
| style="background-color:#91cf61" |Phase I, >20 pts
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1503093 Robert et al. 2015 (KEYNOTE-006)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Ipilimumab_monotherapy_2|Ipilimumab]]
|style="background-color:#1a9850"|Superior OS
|-
|2. Pembrolizumab 10 mg/kg q3wk
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 10 mg/kg IV once on day 1

'''14-day cycles'''

===Variant #3, 10 mg/kg q3wk {{#subobject:e60ce6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126516/ Hamid et al. 2013 (KEYNOTE-001)]
| style="background-color:#91cf61" |Phase I, >20 pts
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00083-2/fulltext Ribas et al. 2015 (KEYNOTE-002)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|Investigator-choice of:<br> 1. [[#Carboplatin_.26_Paclitaxel|Carboplatin & Paclitaxel]]<br> 2. [[#Dacarbazine_monotherapy|Dacarbazine]]<br> 3. [[#Paclitaxel_monotherapy|Paclitaxel]]<br> 4. [[#Temozolomide_monotherapy|Temozolomide]]
|style="background-color:#1a9850"|Superior PFS
|-
|5. Pembrolizumab 2 mg/kg
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa1503093 Robert et al. 2015 (KEYNOTE-006)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Ipilimumab_monotherapy_2|Ipilimumab]]
|style="background-color:#1a9850"|Superior OS
|-
|2. Pembrolizumab 10 mg/kg q2wk
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 10 mg/kg IV over 30 minutes once on day 1

'''21-day cycles'''

===References===
# '''Phase 1:''' Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11;369(2):134-44. Epub 2013 Jun 2. [https://www.nejm.org/doi/full/10.1056/NEJMoa1305133 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126516/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23724846 PubMed]
## '''Update:''' Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109-17. Epub 2014 Jul 14. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960958-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25034862 PubMed]
## '''Update:''' Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19;315(15):1600-9. Erratum in: JAMA. 2016 Jun 14;315(22):2472. [https://jamanetwork.com/journals/jama/fullarticle/2514195 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27092830 PubMed]
# '''KEYNOTE-002:''' Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug;16(8):908-18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00083-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26115796 PubMed]
# '''KEYNOTE-006:''' Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32. Epub 2015 Apr 19. [https://www.nejm.org/doi/full/10.1056/NEJMoa1503093 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25891173 PubMed]
## '''Update:''' Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Oct 21;390(10105):1853-1862. Epub 2017 Aug 16. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31601-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28822576 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.24686 Eisen et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|Lenalidomide
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No active antineoplastic treatment.''
===References===
# Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 2010 Jan 1;116(1):146-54. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.24686 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19862820 PubMed]

==Temozolomide monotherapy {{#subobject:4e2652|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:6e73a5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/18/1/158.long Middleton et al. 2000]
|style="background-color:#1a9851"|Phase III (E)
|[[#Dacarbazine_monotherapy|Dacarbazine]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878048/ Ribas et al. 2013]
|style="background-color:#1a9851"|Phase III (C)
|Tremelimumab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5, taken while fasting

'''28-day cycles'''

===References===
# Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000 Jan;18(1):158-66. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. [http://jco.ascopubs.org/content/18/1/158.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10623706 PubMed]
<!-- Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2008, and 25th Annual Meeting of the International Society for Biological Therapy of Cancer, Washington, DC, October 2-4, 2010. -->
# Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10;31(5):616-22. Epub 2013 Jan 7. [http://ascopubs.org/doi/full/10.1200/JCO.2012.44.6112 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878048/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23295794 PubMed]

==Temozolomide & Bevacizumab {{#subobject:511376|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TB: '''<u>T</u>'''emozolomide & '''<u>B</u>'''evacizumab
===Regimen {{#subobject:42ead6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089063/ Kottschade et al. 2013 (N0775)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#ABC|ABC]]
|style="background-color:#fc8d59"|Seems to have inferior PFS6
|-
|}
====Chemotherapy====
*[[Temozolomide (Temodar)]] 200 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===References===
<!-- This study was presented at the American Society for Clinical Oncology 2011 Annual Meeting, June 3 to 7, Chicago, Illinois, as a poster discussion. -->
# Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML, Markovic SN. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer. 2013 Feb 1;119(3):586-92. Epub 2012 Aug 22. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.27760/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089063/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22915053 PubMed]

=Maintenance immunotherapy for metastatic or unresectable disease=

==IL-2 monotherapy {{#subobject:fa72a9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for IL-2 maintenance biotherapy in melanoma]]

===Regimen {{#subobject:2ed5d3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://clincancerres.aacrjournals.org/content/8/9/2775.long O'Day et al. 2002]
|style="background-color:#91cf61"|Phase II
|-
|}
====Immunotherapy, low-dose cycles (1, 4, 7, 9, 11)====
*[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] 1,000,000 units/m<sup>2</sup> SC once per day every Monday to Friday on days 1 to 28

====Supportive medications====
*[[Sargramostim (Leukine)]] 125 mcg/m<sup>2</sup> SC once per day on days 1 to 14

'''28-day cycles, alternating with pulse cycles:'''

====Immunotherapy, pulse cycles (2, 3, 5, 6, 8, 10, 12)====
*[[Aldesleukin (Proleukin)|IL-2 - Aldesleukin (Proleukin)]] 18,000,000 units/m<sup>2</sup> IV continuous infusion over 6 hours, then 18,000,000 units/m<sup>2</sup> IV continuous infusion over 12 hours, then 18,000,000 units/m<sup>2</sup> IV continuous infusion over 24 hours on days 1 to 2
**Then as an outpatient: 1,000,000 units/m<sup>2</sup> SC once per day every Monday to Friday on days 3 to 28

====Supportive medications====
*[[Sargramostim (Leukine)]] 125 mcg/m<sup>2</sup> SC once per day on days 3 to 17 (note: this was possibly a typo in O'Day et al. 2002 since shifting the schedule 2 days forward would be days 3 to 16)
*[[Ondansetron (Zofran)]] 32 mg IV or [[Granisetron]] 2 mg IV once per day 
*[[Omeprazole (Prilosec)]] 20 mg PO QPM
*[[Acetaminophen (Tylenol)]] 650 mg PO every 4 hours, starting prior to IL-2 and continuing on days 1 & 2
*[[Meperidine (Demerol)]] 25 mg IV every 6 hours as needed for chills and rigors

'''28-day cycles, alternating with low-dose cycles, for a total of 12 cycles'''

===References===
# O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, Fournier P, Gammon G. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res. 2002 Sep;8(9):2775-81. [http://clincancerres.aacrjournals.org/content/8/9/2775.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12231516 PubMed]

==Ipilimumab monotherapy {{#subobject:34ee90|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a89958|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/21/8/1712.long O'Day et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1104621 Robert et al. 2011 (CA184-024)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70090-6/abstract Margolin et al. 2012]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*O'Day et al. 2010 and Margolin et al. 2012: [[#Ipilimumab_monotherapy_2|Ipilimumab induction]] x 4
*CA184-024: [[#Dacarbazine_.26_Ipilimumab|Dacarbazine & Ipilimumab]]
====Immunotherapy====
*[[Ipilimumab (Yervoy)]] 10 mg/kg IV once on day 1

'''12-week cycles'''

===References===
# O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug;21(8):1712-7. Epub 2010 Feb 10. [http://annonc.oxfordjournals.org/content/21/8/1712.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20147741 PubMed]
# '''CA184-024:''' Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. Epub 2011 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1104621 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21639810 PubMed]
## '''Update:''' Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015 Apr 1;33(10):1191-6. Epub 2015 Feb 23. [http://jco.ascopubs.org/content/33/10/1191.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25713437 PubMed]
# Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012 May;13(5):459-65. Epub 2012 Mar 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70090-6/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22456429 PubMed]

==Ipilimumab & Nivolumab {{#subobject:28103f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:6cf5ae|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1414428 Postow et al. 2015 (CheckMate 069)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Ipilimumab_.26_Nivolumab|Ipilimumab & Nivolumab induction]]
====Immunotherapy====
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1, '''given second'''
*[[Nivolumab (Opdivo)]] 1 mg/kg IV once on day 1, '''given first'''

'''12-week cycle for 8 cycles'''

===References===
# '''CheckMate 069:''' Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006-17. Epub 2015 Apr 20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1414428 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25891304 PubMed]
## '''Update:''' Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1558-1568. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30366-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27622997 PubMed]

==Nivolumab monotherapy {{#subobject:04c9a8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, indefinite {{#subobject:157139|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30126-7/fulltext Weber et al. 2016 (CheckMate 064)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Nivolumab.2C_then_Ipilimumab|Nivolumab, then Ipilimumab induction]] versus [[#Ipilimumab.2C_then_Nivolumab|Ipilimumab, then Nivolumab induction]]
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
**Notably, on 9/13/16 the [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm FDA recommended] that dosing for this indication be changed to 240 mg with the same schedule based on updated pharmacokinetic data.

'''14-day cycles'''

===Variant #2, 2-year course {{#subobject:f7d279|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837092/ Weber et al. 2013]
|style="background-color:#ffffbe"|Phase I
|-
|}
====Preceding treatment====
*[[#Nivolumab_monotherapy|Nivolumab induction]]
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1
**Notably, on 9/13/16 the [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm FDA recommended] that dosing for this indication be changed to 240 mg with the same schedule based on updated pharmacokinetic data.

'''12-week cycle for 2 years'''

===References===
# '''Phase I:''' Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec 1;31(34):4311-8. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837092/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24145345 PubMed]
# '''CheckMate 064:''' Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):943-55. Epub 2016 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30126-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474305/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27269740 PubMed]

[[Category:Melanoma regimens]]
[[Category:Disease-specific pages]]
[[Category:Skin cancers]]
